Is Obinituzumab the most Cost-Effective Biological Therapy for Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia in Colombia?
May 1, 2016, 00:00
10.1016/j.jval.2016.03.1602
https://www.valueinhealthjournal.com/article/S1098-3015(16)01670-3/fulltext
Title :
Is Obinituzumab the most Cost-Effective Biological Therapy for Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia in Colombia?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01670-3&doi=10.1016/j.jval.2016.03.1602
First page :
A152
Section Title :
Cancer - Cost Studies
Open access? :
No
Section Order :
325